154.01
1.84 (1.21%)
| Penutupan Terdahulu | 152.17 |
| Jumlah Dagangan | 82,710 |
| Harga / Pendapatan (P/E Ke hadapan) | 380.25 |
| Harga / Buku (P/B) | 7.89 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.37% |
| Nisbah Semasa (MRQ) | 25.98 |
| Aliran Tunai Operasi (OCF TTM) | -29.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.42 M |
| Pulangan Atas Aset (ROA TTM) | -22.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Belite Bio, Inc | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | 2.0 |
| Volatiliti Harga | 2.4 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.40 |
|
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 53.93% |
| % Dimiliki oleh Institusi | 0.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2026 | 3,077,219 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CHUANG HAO-YUAN | 150.28 | - | 5,000 | 751,400 |
| LIN YU-HSIN | 150.28 | - | 5,000 | 751,400 |
| Jumlah Keseluruhan Kuantiti Bersih | 10,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 1,502,800 | |||
| Purata Pembelian Keseluruhan ($) | 150.28 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LIN YU-HSIN | Pegawai | 29 Oct 2026 | Diperolehi (+) | 5,000 | 150.28 | 751,400 |
| CHUANG HAO-YUAN | Pegawai | 29 Oct 2026 | Diperolehi (+) | 5,000 | 150.28 | 751,400 |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |